A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The DNA damage response kinase ATR may be a useful cancer therapeutic target. ATR inhibition synergizes with loss of ERCC1, ATM, XRCC1 and DNA damaging chemotherapy agents. Clinical trials have begun using ATR inhibitors in combination with cisplatin. Here we report the first synthetic lethality screen with a combination treatment of an ATR inhibitor (ATRi) and cisplatin. Combination treatment with ATRi/cisplatin is synthetically lethal with loss of the TLS polymerase ζ and 53BP1. Other DNA repair pathways including homologous recombination and mismatch repair do not exhibit synthetic lethal interactions with ATRi/cisplatin, even though loss of some of these repair pathways sensitizes cells to cisplatin as a single-agent. We also report that ATRi strongly synergizes with PARP inhibition, even in homologous recombination-proficient backgrounds. Lastly, ATR inhibitors were able to resensitize cisplatin-resistant cell lines to cisplatin. These data provide a comprehensive analysis of DNA repair pathways that exhibit synthetic lethality with ATR inhibitors when combined with cisplatin chemotherapy, and will help guide patient selection strategies as ATR inhibitors progress into the cancer clinic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig 3 siRNA screen identifies synthetic lethal interactions with cisplatin and ATR inhibitor treatment. (A) Schematic of the siRNA screen. U2OS cells were transfected with siRNAs and then either left untreated or treated with 1μM ATRi, 0.5μM cisplatin, or ATRi and cisplatin. Cell viability was measured with alamar blue. (B) Viability of the non-targeting (NT) and ATR siRNA controls using the screen conditions. The values represent the mean ± SD of the three independent replicates of the screen. (C-E) The robust z-scores of treated compared with untreated cell viability were determined for each siRNA in the library for ATRi (C), cisplatin (D), and ATRi and cisplatin (E). The red circles represent the 8 unique siRNAs targeting ATR and ATRIP present in the library and the red line indicates a robust z score of -1.3. (F) Summary of the overlap of synthetic lethal relationships with ATRi, cisplatin, or ATRi and cisplatin. (G) Complete list of genes that exhibit a synthetic lethal relationship with ATRi, cisplatin, or ATRi and cisplatin. Genes with 2 or more siRNAs with robust z-scores of less than -1.3 are considered as synthetic lethal. The ATRi single-agent screen was previously published and included for comparison to the other drug treatments [18].](https://figures.cochat.ai/paper-figures/7ad76d20db1144d5b250ea00de8c7482/a-synthetic-lethal-screen-identifies-dna-repair-pathways-that-sensitize-cancer-figure-3.jpg)






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In a clinical context, this increase could lead to an inflammatory response and additional tissue damage, which contrasts with the less inflammatory (and more controlled) apoptosis [38, 39, 40].”
From Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models (2024) · cites this paper as [40]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 2×
“REV3 is also located within a fragile site deleted in several types of human leukemias and solid tumors [50], and 7% of B cell lymphomas in the TCGA data set have homozygous deletions in REV3 [49] making the synthetic lethal relationship with ATRi/cisplatin potentially useful clinically.”
BackgroundTargeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192 · cited 1×
“The PARP inhibitor BMN673 is 100-fold more potent at trapping PARP-DNA complexes than Olaparib or Veliparib [52] and functions by potently trapping PARP-DNA complexes, which are likely repaired by HR during DNA replication [26, 34].”
BackgroundActivation of the DNA damage checkpoint and genomic instability in human precancerous lesions
Gorgoulis, V. G., Vassiliou, L.-V. F., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., DiTullio, R. A., Kastrinakis, N. G., Levy, B., et al. (2005) · Nature · doi:10.1038/nature03485 · Cited by 2,009
ATR: an essential regulator of genome integrity
Cimprich, K. A., & Cortez, D. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2450 · Cited by 1,798 · cited 2×
“The DNA damage response kinase ATR (ATM- and Rad3-related) coordinates many of the cellular responses to DNA damage ATR is necessary to stabilize stalled replication forks and allow fork restart after damage [9].”
BackgroundSelf-citation53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Bunting, S. F., Callén, E., Wong, N., Chen, H.-T., Polato, F., Gunn, A., Bothmer, A., Feldhahn, N., Fernandez-Capetillo, O., Cao, L., et al. (2010) · Cell · doi:10.1016/j.cell.2010.03.012 · Cited by 1,671
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434 · cited 1×
“Isobologram analysis was performed as described [29, 30].”
Cited by
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Yazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395
ATR/CHK1 inhibitors and cancer therapy
Qiu, Z., Oleinick, N. L., & Zhang, J. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.09.043 · Cited by 370
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Berti, M., Cortez, D., & Lopes, M. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0257-5 · Cited by 329
Self-citationLecona, E., & Fernandez-Capetillo, O. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0034-3 · Cited by 325
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
“186).”
Nyquist, M. D., Corella, A., Coleman, I., De Sarkar, N., Kaipainen, A., Ha, G., Gulati, R., Ang, L., Chatterjee, P., Lucas, J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107669 · Cited by 292
“Previous studies have shown synergistic effects of PARP and ATR inhibition in the context of homology-directed DNA repair deficiency and the potential for ATR inhibition to overcome resistance to PARP inhibition (Mohni et al., 2015; Wengner et al., 2020).”
BackgroundMolecular Pathways: Targeting ATR in Cancer Therapy
Karnitz, L. M., & Zou, L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0479 · Cited by 265
“tumor hypoxia, XRCC1 and ERCC1 deficiencies, and reliance on the ALT pathway also render cells more sensitive to ATR inhibition (28-31, 34, 37), although these potential biomarkers have not yet been as extensively examined”
BackgroundInfluentialVendetti, F. P., Lau, A., Schamus, S., Conrads, T. P., O’Connor, M. J., & Bakkenist, C. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6247 · Cited by 239
“Furthermore, ATR kinase inhibitors synergize with loss of ERCC1, ATM, XRCC1, and DNA damaging chemotherapy agents in tissue culture [26, 30, 31].”
BackgroundExploiting DNA Replication Stress for Cancer Treatment
Ubhi, T., & Brown, G. W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3631 · Cited by 230
“Given their mechanisms of action, ATR and CHK1 inhibitors synergize with compounds that induce replication stress, and increase the toxicity of nucleoside analogues in ovarian, lung, and pancreatic cancer (56–60), platinum-based agents in lung, gastric, ovarian, bladder, and breast cancer (50, 61, 62) and topoisomeras…”
BackgroundTargeting the ATR-CHK1 Axis in Cancer Therapy
Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 231
“In addition, in two synthetic lethal screens using the ATR inhibitor VE-821, genes in the ATR/CHK1 pathway itself, including: ATR, ATRIP, RPA, Claspin, Hus1, RAD1 and CHK1 were the strongest hits [126,134].”
BackgroundHMCES Maintains Genome Integrity by Shielding Abasic Sites in Single-Strand DNA
Mohni, K. N., Wessel, S. R., Zhao, R., Wojciechowski, A. C., Luzwick, J. W., Layden, H., Eichman, B. F., Thompson, P. S., Mehta, K. P. M., & Cortez, D. (2019) · Cell · doi:10.1016/j.cell.2018.10.055 · Cited by 180
Self-citationEndometrial cancer: Molecular markers and management of advanced stage disease
Arend, R. C., Jones, B. A., Martinez, A., & Goodfellow, P. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.05.015 · Cited by 174
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Bradbury, A., Hall, S., Curtin, N., & Drew, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107450 · Cited by 171
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
Carrassa, L., & Damia, G. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.013 · Cited by 170
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K., Bailey, P., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 162
Drugging the Cancers Addicted to DNA Repair
Nickoloff, J. A., Jones, D., Lee, S.-H., Williamson, E. A., & Hromas, R. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx059 · Cited by 159
“Not surprisingly, PARP1 inhibition synergizes with ATR blockade (123).”
BackgroundDancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Minchom, A. R., Aversa, C., & Lopez, J. S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918786658 · Cited by 151
Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications
Toh, M.-R., & Ngeow, J. Y. Y. (2021) · The Oncologist · doi:10.1002/onco.13829 · Cited by 140
“Exploiting this phenomenon, researchers inhibited ATR and resensitized chemoresistant cancer cells to platinum agents and PARPi [23, 25].”
BackgroundRadiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei
Dillon, M. T., Barker, H. E., Pedersen, M., Hafsi, H., Bhide, S. A., Newbold, K. L., Nutting, C. M., McLaughlin, M., & Harrington, K. J. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0239 · Cited by 141
APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition
Buisson, R., Lawrence, M. S., Benes, C. H., & Zou, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3389 · Cited by 139
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
Górecki, L., Andrš, M., Řezáčová, M., & Korábečný, J. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107518 · Cited by 128
Functional Analysis of the Replication Fork Proteome Identifies BET Proteins as PCNA Regulators
Wessel, S. R., Mohni, K. N., Luzwick, J. W., Dungrawala, H., & Cortez, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.051 · Cited by 126
Self-citationTargeting the Checkpoint to Kill Cancer Cells
Benada, J., & Macůrek, L. (2015) · Biomolecules · doi:10.3390/biom5031912 · Cited by 124
“Finally, several genetically-determined defects in DNA repair (such as loss of XRCC1 or translesion polymerase REV3L) are synthetically lethal in combination with the treatment with ATR inhibitors and cisplatin [75,76].”
BackgroundSynthetically Lethal Interactions of ATM, ATR, and DNA-PKcs
Kantidze, O. L., Velichko, A. K., Luzhin, A. V., Petrova, N. V., & Razin, S. V. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.09.007 · Cited by 115
Directing the use of DDR kinase inhibitors in cancer treatment
Brandsma, I., Fleuren, E. D. G., Williamson, C. T., & Lord, C. J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1389895 · Cited by 119
“Furthermore, it has been demonstrated that BRCA1-deficient cells that have become PARP inhibitor resistant due to loss of either of two DNA repair proteins 53BP1 or REV7, can be resensitized to PARPi via exposure to an ATMi [73,74].”
BackgroundInfluentialA consensus set of genetic vulnerabilities to ATR inhibition
Hustedt, N., Álvarez-Quilón, A., McEwan, A., Yuan, J. Y., Cho, T., Koob, L., Hart, T., & Durocher, D. (2019) · Open Biology · doi:10.1098/rsob.190156 · Cited by 108
Challenging Standard-of-Care Paradigms in the Precision Oncology Era
Subbiah, V., & Kurzrock, R. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2017.12.004 · Cited by 89
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
Targeting ATR in cancer medicine
Sundar, R., Brown, J. S., Garces, A. I., & Yap, T. A. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.05.002 · Cited by 85
Translational research in radiation-induced DNA damage signaling and repair
Nickoloff, J. A., Boss, M., Allen, C., & LaRue, S. Μ. (2017) · Translational Cancer Research · doi:10.21037/tcr.2017.06.02 · Cited by 72
“Personalizing cancer therapy based on known defects in DDR factors through synthetic lethal approaches is a rapidly expanding research area, both in the lab and in clinical practice (2,4,6-10,12,13,107-111).”
BackgroundGomes, L. R., Rocha, C. R. R., Martins, D. J., Fiore, A. P. Z. P., Kinker, G. S., Bruni‐Cardoso, A., & Menck, C. F. M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1689-8 · Cited by 71
ATR Is a Therapeutic Target in Synovial Sarcoma
Jones, S. E., Fleuren, E. D. G., Frankum, J. R., Konde, A., Williamson, C. T., Krastev, D. B., Pemberton, H. N., Campbell, J., Gulati, A., Elliott, R. J. R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2056 · Cited by 61
“Synergistic effects of combined ATR and PARP inhibition have been reported in other tumour types as well (42-44).”
Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors
Henssen, A. G., Reed, C., Jiang, E., García, H. D., von Stebut, J., MacArthur, I. C., Hundsdoerfer, P., Kim, J. H., de Stanchina, E., Kuwahara, Y., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam9078 · Cited by 64
“The magnitude of this effect appeared as substantial as compared to the previously reported effects of AZD6738 against tumors with genetic deficiencies of ATM, XRCC1 or ERCC1 (35-38).”
ResultInhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
Lodovichi, S., Cervelli, T., Pellicioli, A., & Galli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186684 · Cited by 59
“Some studies are developing small ligands able to inhibit TP53BP1 by binding to its interacting domain and competing with regular substrates, making it unable to coordinate downstream effectors [146,147], moreover a synthetic lethal interaction between TP53BP1 loss and treatment with ATR inhibitors and cisplatin has b…”
BackgroundCombined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status
Hafsi, H., Dillon, M. T., Barker, H. E., Kyula, J., Schick, U., Paget, J. T.-E. H., Smith, H. G., Pedersen, M., McLaughlin, M., & Harrington, K. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00245 · Cited by 55
“This has proven to be the case with PARP inhibition (PARPi) which displays synergistic activity in combination with ATRi in BRCA-mutant ovarian (32, 33), SLFN11-negative prostate, leukemia, and Ewing’s sarcoma cell lines (34) as well as in HR-proficient cell lines (35).”
BackgroundKim, D.-S., Liu, Y., Oberly, S., Freire, R., & Smolka, M. B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky625 · Cited by 59
“Overall, the described findings are consistent with previous reports that showed synthetic lethality of ATR and PARP inhibition in cancer cells and tumors (46,88).”
ATR inhibition sensitizes HPV− and HPV+ head and neck squamous cell carcinoma to cisplatin
Leonard, B. C., Lee, E. D., Bhola, N. E., Li, H., Sogaard, K. K., Bakkenist, C. J., Grandis, J. R., & Johnson, D. E. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.05.028 · Cited by 53
“Moreover, treatment with ATR inhibitors has been shown to enhance cell death induced by chemotherapy drugs and radiation in cancer cell lines in vitro (19-21,23-30).”
BackgroundDiverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis
Yang, Y., Gao, Y., Zlatanou, A., Tateishi, S., Yurchenko, V., Rogozin, I. B., & Vaziri, C. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1456296 · Cited by 53
“Indeed, ablation of REV3 and REV7 (subunits of the TLS polymerase Pol z ) sensitizes cancer cells to a combination of ATRi and cisplatin [107].”
Schepis, T., Lucia, S. S. D., Pellegrino, A., GAUDIO, A. D., Maresca, R., Coppola, G., Chiappetta, M. F., Gasbarrini, A., Franceschi, F., Candelli, M., et al. (2023) · Cancers · doi:10.3390/cancers15133423 · Cited by 59
XRCC2 Regulates Replication Fork Progression during dNTP Alterations
Saxena, S., Somyajit, K., & Nagaraju, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.085 · Cited by 45
Hu, H., Zhao, X., Kaushik, S., Robillard, L., Barthelet, A., Lin, K., Shah, K. N., Simmons, A. D., Raponi, M., Harding, T. C., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.093 · Cited by 42
Hocke, S., Guo, Y., Job, A., Orth, M., Ziesch, A., Lauber, K., Toni, E. N. D., Gress, T. M., Herbst, A., Göke, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6857 · Cited by 42
“In addition, very recent data published during the writing of this manuscript retrieved some of the hits obtained in our genetic ATR model, including especially POLD1 and PRIM1, in a less ATRspecific synthetic lethal screen using ATR-inhibitors [36].”
ResultInfluentialVendetti, F. P., Pandya, P., Clump, D. A., Schamus-Haynes, S., Tavakoli, M., diMayorca, M. S., Islam, N. M., Chang, J., Delgoffe, G. M., Beumer, J. H., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.165615 · Cited by 41
“Gating strategies are shown in Supplemental Figures 9–14.”
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Sule, A. D., Doorn, J. V., Sundaram, R. K., Ganesa, S., Vasquez, J. C., & Bindra, R. S. (2021) · NAR Cancer · doi:10.1093/narcan/zcab018 · Cited by 40
“As reported previously (36,37), we also saw some cytotoxicity of the combination in the WT cells, however the cytotoxicity in the IDH1-mutant cells was more heightened.”
BackgroundPrincipe, D. R. (2022) · Cancers · doi:10.3390/cancers14040897 · Cited by 41
“In breast cancer cells, the combination of the ATR inhibitor VE-821 and PARP inhibitors synergize to promote cell death independent of HR-proficiency [58], and ATR inhibition via VE-821 overcomes PARP inhibitor resistance in BRCA-deficient cells by disrupting rewired HR and fork protection pathways [59].”
BackgroundBarnes, R. P., Tsao, W.-C., Moldovan, G., & Eckert, K. A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3931 · Cited by 39
Tonzi, P., & Huang, T. T. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.03.016 · Cited by 39
“Both Pol Eta and Pol Iota were hits in a siRNA screen identifying genes synthetically lethal with ATR inhibitor [72].”
BackgroundLamberti, G., Andrini, E., Sisi, M., Federico, A. D., & Ricciuti, B. (2020) · Future Oncology · doi:10.2217/fon-2020-0215 · Cited by 36
Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer
Xie, Y., Xiao, D., Li, D., Peng, M., Peng, W., Duan, H., & Yang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1441222 · Cited by 41
Southgate, H. E. D., Chen, L., Tweddle, D. A., & Curtin, N. J. (2020) · Cancers · doi:10.3390/cancers12051095 · Cited by 35
“ATR inhibition has been shown to enhance PARP inhibitor sensitivity in a variety of adult solid tumour types [51,62,63] and overcome resistance to PARP inhibitors [52,64].”
BackgroundPARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapy
Kulkarni, S., Seneviratne, N., Tosun, Ç., & Madhusudan, S. (2025) · DNA repair · doi:10.1016/j.dnarep.2025.103830 · Cited by 40
Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs
Jackson, R. A., & Chen, E. S. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.014 · Cited by 42
Schleicher, E. M., Dhoonmoon, A., Clements, K. E., Jackson, L. M., Stump, C. L., Nicolae, C. M., & Moldovan, G. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009176 · Cited by 34
“ATR inhibitors may also be used in combination with DNA damaging agents as a therapeutic option [7, 8].”
BackgroundCancer TARGETases: DSB repair as a pharmacological target
Samadder, P., Aithal, R., Beláň, O., & Krejčí, L. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.007 · Cited by 35
Critical DNA damaging pathways in tumorigenesis
Kloeber, J. A., & Lou, Z. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.012 · Cited by 30
The CINs of Polo-Like Kinase 1 in Cancer
Cunningham, C. E., MacAuley, M. J., Vizeacoumar, F. S., Abuhussein, O., Freywald, A., & Vizeacoumar, F. J. (2020) · Cancers · doi:10.3390/cancers12102953 · Cited by 31
Tetratricopeptide repeat factor XAB2 mediates the end resection step of homologous recombination
Onyango, D. O., Howard, S. M., Neherin, K., Yanez, D. A., & Stark, J. M. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw275 · Cited by 27
Ekstrom, T. L., Pathoulas, N. M., Huehls, A. M., Kanakkanthara, A., & Karnitz, L. M. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1099 · Cited by 25
“HR defects are associated with better survival following platinum-based chemotherapy (4, 5), likely due to the fact that platinum therapies induce lesions that are repaired by HR (6, 7).”
InfluentialChau, V. T., Liu, W., de Thoré, M. G., Meziani, L., Mondini, M., O’Connor, M. J., Deutsch, É., & Clémenson, C. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0931-6 · Cited by 25
Sugitani, N., Vendetti, F. P., Cipriano, A. J., Pandya, P., Deppas, J. J., Moiseeva, T. N., Schamus-Haynes, S., Wang, Y., Palmer, D., Osmanbeyoglu, H. U., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111371 · Cited by 23
Karukonda, P., Odhiambo, D. A., & Mowery, Y. M. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23384 · Cited by 22
Gallo, D., & Brown, G. W. (2019) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2019.1651817 · Cited by 23
“Pol g is also synthetic lethal with ATR inhibition when combined with aphidicolin treatment (Barnes et al. 2018).”
BackgroundGenta, S., Martorana, F., Stathis, A., & Colombo, I. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103539 · Cited by 20
Targeting the CINful genome: Strategies to overcome tumor heterogeneity
Cunningham, C. E., MacAuley, M. J., Yadav, G., Vizeacoumar, F. S., Freywald, A., & Vizeacoumar, F. J. (2019) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2019.02.006 · Cited by 21
Yin, Z., Chen, E., Cai, X., Gong, E., Li, Y., Xu, C., Ye, Z., Cao, Z., & Pan, J. (2021) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2021.1892132 · Cited by 18
“ATR inhibitors exhibit synthetic lethal interactions, with deficiencies in the DNA damage response enzymes ATM and XRCC1 and with overexpression of the cell cycle kinase cyclin E [35,36].”
BackgroundRamachandran, S. A., Jadhavar, P. S., Singh, M. P., Sharma, A., Bagle, G. N., Quinn, K. P., Wong, P. A., Protter, A. A., Rai, R., Pham, S. M., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.01.045 · Cited by 17
ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma
Seidel, P., Rubarth, A., Zodel, K., Peighambari, A., Neumann, F., Federkiel, Y., Huang, H., Hoefflin, R., Adlesic, M., Witt, C. C., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.156087 · Cited by 16
Kulkarni, S., Gajjar, K. B., & Madhusudan, S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1414112 · Cited by 16
Translation of Targeted Radiation Sensitizers into Clinical Trials
Reichert, Z. R., Wahl, D. R., & Morgan, M. A. (2016) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2016.06.001 · Cited by 17
Heyza, J. R., Ekinci, E., Lindquist, J., Lei, W. H., Yunker, C. K., Vinothkumar, V., Rowbotham, R., Polin, L., Snider-Hoy, N. G., Buren, E. C. V., et al. (2023) · NAR Cancer · doi:10.1093/narcan/zcac045 · Cited by 16
Ho, C. K., Kornaga, E. N., Klimowicz, A. C., Enwere, E. K., Dean, M. L., Bebb, G. D., Phan, T., Ghatage, P., Magliocco, A. M., Lees‐Miller, S. P., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.025 · Cited by 14
Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis
Biswas, H., Makinwa, Y., & Zou, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411684 · Cited by 15
“Multiple investigations have indicated that ATR inhibitors synergize with genotoxins more efficiently in cells with p53 abnormalities than in p53-proficient cells [37,42,44,48,56] as a result of the loss of the G1 checkpoint and/or higher replication stress caused by relaxed S-phase entrance [34].”
BackgroundJob, A., Tatura, M., Schäfer, C., Lutz, V., Schneider, H., Lankat–Buttgereit, B., Zielinski, A., Borgmann, K., Bauer, C. A., Gress, T. M., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76033-1 · Cited by 15
Jess, J., Sorensen, K. M., Boguslawski, E. A., Stout, M. C., Madaj, Z., Caiello, B. P., Pomaville, M. M., Wilson, E. R., Kinn-Gurzo, S. S., Parker, C. C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3063 · Cited by 14
Claspin: From replication stress and DNA damage responses to cancer therapy
Azenha, D., Lopes, M. C., & Martins, T. (2018) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.10.007 · Cited by 14
Exploiting the DNA Damage Response for Prostate Cancer Therapy
Stracker, T. H., Osagie, O. I., Escorcia, F. E., & Citrin, D. E. (2023) · Cancers · doi:10.3390/cancers16010083 · Cited by 12
Krishnamurthy, A., Wang, H., Rhee, J. C., Davar, D., Moy, R. H., Ratner, L., Christner, S. M., Holleran, J. L., Deppas, J. J., Sclafani, C. R., et al. (2025) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04745-6 · Cited by 10
“ATR kinase inhibition potentiates chemo-therapies that target DNA replication forks, target tumors with inactivating mutations in ATM, ERCC1, RNASE H2, and XRCC1, and block the upregulation of PD-L1 on tumor cells after radiation [7, 10–13].”
DNA damage response as a therapeutic target in gynecological cancers
Leary, A. F., Auguste, A., & Mesnage, S. J. L. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000320 · Cited by 10
“Given evidence of synergy between ATR and PARP inhibition, and ATR inhibition and platinum-chemotherapy [26], these combinations are being tested in early ovarian cancer trials (NCT02627443, NCT02595892).”
BackgroundDing, J., Chen, Z., Ding, W., Xiang, Y., & Yang, J. (2023) · Autoimmunity · doi:10.1080/08916934.2023.2234101 · Cited by 9
“Accumulating evidence has revealed that Pol ζ is the potential target to enhance the chemoradiotherapy sensitivity of cancer cells [18,19].”
BackgroundBeyaert, M., Starczewska, E., Gonzalez-Perez, A. C., Vanlangendonck, N., Saussoy, P., Tilman, G., Leener, A. D., Vekemans, M., Neste, E. V. D., & Bontemps, F. (2017) · Oncotarget · doi:10.18632/oncotarget.18144 · Cited by 11
Anomalies de la réparation de l’ADN et cancers gynécologiques
Auguste, A., & Leary, A. F. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.09.007 · Cited by 8
Disrupting PHF8-TOPBP1 connection elicits a breast tumor-specific vulnerability to chemotherapeutics
Ma, S., Zhang, J., Guo, Q., Cao, C., Bao, K., Liu, L., Chen, C. D., Liu, Z., Yang, J., Yang, N., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.010 · Cited by 8
NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage
Alonso‐Marañón, J., Solé, L., Villanueva, D. A., Maqueda, M., Lobo‐Jarne, T., Montoto, Á., Yélamos, J., Borràs, E., Uraga, L., Hooper, C., et al. (2025) · Science Signaling · doi:10.1126/scisignal.adr0128 · Cited by 7
Wei, W., Shi, F., Xu, Y., Jiao, Y., Zhang, Y., Ou, Q., Wu, X., Yang, L., & Lai, J. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04634-1 · Cited by 8
Kiesel, B. F., Shogan, J. C., Rachid, M., Parise, R. A., Vendetti, F. P., Bakkenist, C. J., & Beumer, J. H. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.01.055 · Cited by 7
Zhao, J., Yang, J., Li, K., Chen, Y., Tang, M., Zhu, H.-L., Nie, C.-I., Yuan, Z., & Zhao, X.-Y. (2023) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2023.110740 · Cited by 6
Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70294 · Cited by 5
The DNA Damage Response: Roles in Cancer Etiology and Treatment
Butler, L. R., Gilad, O., & Brown, E. J. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-75836-7_2 · Cited by 5
Recent Advances in Therapeutic Application of DNA Damage Response Inhibitors against Cancer
Fernandes, S. G., Shah, P., & Khattar, E. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210608105735 · Cited by 4
Tsung, I., Smith, D. C., Heath, E. I., Cackowski, F. C., Devitt, M. E., Braun, T., Yentz, S. E., Nguyen, C. B., Chinnaiyan, A. M., Shah, N., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00457 · Cited by 5
Targeting ATR for Cancer Therapy: ATR-Targeted Drug Candidates
Dillon, M. T., & Harrington, K. J. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-75836-7_5 · Cited by 4
Targeting the Ataxia Telangiectasia and Rad3 Signaling Pathway to Overcome Chemoresistance in Cancer
Kwok, M., & Stanković, T. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00010-x · Cited by 3
Integrating genomic information and signaling dynamics for efficient cancer therapy
Stewart-Ornstein, J., & Lahav, G. (2016) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2016.12.013 · Cited by 2
Chen, M., Marrs, B., Qi, L., Knifley, T., Jarrett, S. G., Weiss, H. L., Stewart, R. L., D'Orazio, J. A., & O’Connor, K. L. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/785873 · Cited by 1
“We find in the literature (41,42) and our data (Figs.”
BackgroundMerrikh, H. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734636888.793557375 · Cited by 1
ATR Kinase Inhibition Induces Thymineless Death in Proliferating CD8 + T CellsPreprint
Sugitani, N., Vendetti, F. P., Cipriano, A. J., Deppas, J. J., Moiseeva, T. N., Schamus-Haynes, S., Wang, Y., Palmer, D., Osmanbeyoglu, H. U., Bostwick, A., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4093292 · Cited by 1
Targeting ATR for Cancer Therapy: Profile and Expectations for ATR Inhibitors
Curtin, N. J., & Pollard, J. R. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-75836-7_4
Bhakuni, R., Shaik, A., & Kirubakaran, S. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00845
Regulation of the ATR Pathway in the Replication Stress Response
Luzwick, J. W. (2016)
Self-citation
Metadata
- Authors
- Mohni, K. N., Thompson, P. S., Luzwick, J. W., Glick, G. G., Pendleton, C. S., Lehmann, B. D., Pietenpol, J. A., & Cortez, D.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Cortez, David
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2015-05-12
- Volume
- 10
- Issue
- 5
- Pages
- e0125482
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4428765
- OpenAlex
- W1591550632
- Cited by
- 108
- References
- 54
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 10 · 2022: 8 · 2021: 8 · 2020: 11 · 2019: 12 · 2018: 19 · 2017: 18 · 2016: 9 · 2015: 3
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Breast Cancer Research Foundation (PDF14302198)
- National Institutes of Health (CA95131)
- National Cancer Institute (R01CA102729, T32CA093240, CA95131, CA 102792, R01CA102792, T32CA009582)
- National Institute of General Medical Sciences (T32GM007347)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- ATR inhibitors, cisplatin, synthetic lethality, DNA repair pathways, DNA damage response, 53BP1, homologous recombination, DNA mismatch repair, PARP inhibition, cisplatin resistance, combination therapy, cancer therapeutics
- MeSH terms
- Tumor Suppressor p53-Binding Protein 1, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Cisplatin, DNA-Directed DNA Polymerase, DNA Repair, Drug Synergism, Humans, Pyrazines, Sulfones, Gene Library, Drug Resistance, Neoplasm, RNA, Small Interfering, HCT116 Cells, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.